Gilead Sciences Malta EFPIA Report 2023												
Date of publication: 30/06/2024												
Full Name	HCPs: City of Principal Practice HCOs: city where registered	Country of Principal Practice	Principal Practice Address			Contribution to costs of Events (Art 3.01.1.b & 3.01.2.a)			Fee for service and consultancy (Art 3.01.1 c & 3.01.2 c)			TOTAL
(Art 1.01)	(Art 3)	(Schedule 1)	(Art 3)	(Art 3)	(Art 3.01.1.a)	Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract		OPTIONAL
INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: Itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)												
OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons												
Aggregate amount attributable to transfers of value to such Recipients - Art 3.02								€ 6,316.52	€ 3,982.75			€ 10,299.27
Number of Recipients in aggregate disclosure - Art 3.02								6	2			8
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art 3.02								100%	100%			100%
INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)												
OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons												
Aggregate amount attributable to transfers of value to such Recipients - Art 3.02												
Number of Recipients in aggregate disclosure - Art 3.02												
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art 3.02												
	Aggregate amount attributable to tra Number of Recipients in aggregate di % of the number of Recipients includ of Recipients disclosed - Art 3.02 Aggregate amount attributable to tra Number of Recipients in aggregate di % of the number of Recipients in aggregate di % of the number of Recipients includ	Full Name Principal Practice HCOs: city where registered (Art 1.01) (Art 3) (Art 3) Aggregate amount attributable to transfers of value to such Recipients - Art 3 Number of Recipients in aggregate disclosure - Art 3.02 % of the number of Recipients included in the aggregate disclosure in the tot of Recipients disclosed - Art 3.02 Maggregate amount attributable to transfers of value to such Recipients - Art 3 Number of Recipients in aggregate disclosure - Art 3.02 % of the number of Recipients in aggregate disclosure - Art 3.02 % of the number of Recipients in aggregate disclosure - Art 3.02	Full Name Principal Practice HCOs: city where registered Country of Principal Practice Country of Principal Practice (Art 1.01) (Art 3) (Schedule 1) INDIVIDUAL NAMED DISCL Aggregate amount attributable to transfers of value to such Recipients - Art 3.02 Number of Recipients in aggregate disclosure - Art 3.02 % of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art 3.02 Number of Recipients disclosed - Art 3.02 Number of Recipients disclosed - Art 3.02 Number of Recipients in aggregate disclosure - Art 3.02 Number of Recipients in aggregate disclosure - Art 3.02 Number of Recipients in aggregate disclosure - Art 3.02 Number of Recipients in aggregate disclosure - Art 3.02 Number of Recipients in aggregate disclosure - Art 3.02	HCPs: City of Principal Practice HCOs: city where registered (Art 1.01) (Art 3) (Schedule 1) (Art 3) (Schedule 1) (Art 3) (Art 4) (Art 3) (Art 3) (Art 3)	Full Name HCPs: City of Principal Practice HCOs: city where registered (Art 1.01) (Art 3) (Schedule 1) (Art 3) (Schedule 1) (Art 3) (Art 3)	Full Name HCPs: City of Principal Practice HCOs: city where registered (Art 1.01) (Art 3.01 (Art 3.01 (Art 3.01) (Art 3.01 (A	Full Name Principal Practice HCDs: city of Principal Practice HCDs: city where registered Principal Practice HCDs: city where registered (Art 3) (Art 3) (Schedule 1) (Art 3)	Full Name HCS: City of Principal Practice HCOs: city where registered Principal Practice Address (Art 1.01) (Art 3) (Schedule 1) (Art 3) (Schedule 1) (Art 3) (Art 3)	Full Name NCPs: City of Principal Practice Country Principal Practice Address Unique country Identifier OPTIONAL Domains and Grants to NCDs (Art 3.01.1.8) Sponsorship agreements with NCDs (right parties and Grants to NCDs (Art 3.01.1.8) Sponsorship agreements with NCDs (Int parties and Grants to NCDs (Art 3.01.1.8) Sponsorship agreements with NCDs (Int parties applied by NCDs to make a partie of the NCDs (Int parties applied by NCDs to make a partie of the summed up; Itematics about be available for the individual Receptent or public authorities' con Interpret of the parties of value to such Recipients - Art 3.02 C	Full Name HCPs City of Principal Practice Country Principal Practice Principal Pra	Full Name NESP-City of Principal Practice Country Address Address	Full Name Prograft rection registered (Art 1.01) In 1975 City of Processing P

Transfers of Value re Research & Development as defined - Article 3.04 and schedule 1